학술논문
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
Document Type
article
Author
Jens Bauer; Natalie Köhler; Yacine Maringer; Philip Bucher; Tatjana Bilich; Melissa Zwick; Severin Dicks; Annika Nelde; Marissa Dubbelaar; Jonas Scheid; Marcel Wacker; Jonas S. Heitmann; Sarah Schroeder; Jonas Rieth; Monika Denk; Marion Richter; Reinhild Klein; Irina Bonzheim; Julia Luibrand; Ursula Holzer; Martin Ebinger; Ines B. Brecht; Michael Bitzer; Melanie Boerries; Judith Feucht; Helmut R. Salih; Hans-Georg Rammensee; Stephan Hailfinger; Juliane S. Walz
Source
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease with limited therapeutic options. Here, the authors identify the DNAJB1-PRKACA protein as a source for immunogenic neoepitopes and a potential target of T cell-based immunotherapy.